Pharmaceutical composition for treating systemic sclerosis

Provided is a pharmaceutical composition for treating systemic sclerosis, which may be accompanied by progressive dermatitis, containing an IL-17 pathway inhibitor as an active ingredient, as a novel technique useful for treating systemic sclerosis patients, which may be accompanied by progressive dermatitis. The IL-17 pathway inhibitor can be selected from any one or more of an IL-17RA antagonist and an IL-23R antagonist; in particular, it is possible to be any one or more antibodies selected from the group consisting of a Beddalumab, a Juguilliumab, an Eigilliumab, a Nitaziumab, a Bimegniumab, an Usterinum mab, a Tilazumab, a Resazumab, a Meigniumab, a Brukumab, and a Pousaxiumab, or a fragment thereof. 作为对于治疗可伴有进行性皮肤硬化的系统性硬化症患者有用的新技术的提供，提供含有IL-17通路抑制剂作为有效成分的、用于治疗可伴有进行性皮肤硬化的系统性硬化症的药物组合物。IL-17通路抑制剂可以为选自IL-17RA拮抗剂和IL-23R拮抗剂中的任意一种以上，尤其可以为选自由柏达鲁单抗、司库奇尤单抗、依奇珠单抗、尼塔奇单抗、比美吉珠单抗、乌司奴单抗、替拉珠单抗、瑞莎珠单抗、米吉珠单抗、布雷库单抗和古塞奇尤单抗组成的组中的任意一种以上抗体或其片段。